Back |
home / stock / snss / snss message board
Subject | By | Source | When |
---|---|---|---|
https://finance.yahoo.com/news/sunesis-pharmaceuticals-viracta-therapeutics-anno | Techmozz | investorshub | 11/30/2020 1:38:56 PM |
Sunesis Pharmaceutic ($SNSS) | mick | investorshub | 11/17/2020 9:01:29 PM |
I DID NOT $SEE IT MY FRIEND | mick | investorshub | 11/17/2020 8:53:06 PM |
A great ER and the Robinhood DAs are selling. | John_Langston | investorshub | 11/17/2020 3:42:37 PM |
I thought Sunesis was releasing the ER today. | John_Langston | investorshub | 11/09/2020 3:26:10 PM |
Sunesis Pharmaceutic ($SNSS) | mick | investorshub | 10/30/2020 2:14:40 PM |
I added more yesterday. | John_Langston | investorshub | 10/30/2020 1:24:41 PM |
Sunesis Pharmaceutic ($SNSS) | mick | investorshub | 10/29/2020 10:48:47 PM |
...add ingrediency ...blend...cold down....freeze.....warm up and.........KA-$BAM | spacehc | investorshub | 10/29/2020 4:49:51 PM |
Sunesis Pharmaceuticals Announces Presentation of SNS-510 Preclinical Data | mick | investorshub | 10/25/2020 10:08:07 PM |
Sunesis Pharmaceutic ($SNSS) | mick | investorshub | 10/25/2020 10:07:50 PM |
More like Rogersed. | John_Langston | investorshub | 10/23/2020 6:21:08 PM |
News, Short Squeeze, Breakout and More Instantly...
Viracta Therapeutics Inc Com Company Name:
SNSS Stock Symbol:
NASDAQ Market:
Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement Shares of Viracta to commence trading on the Nasdaq Global Select Market on February 25, 2021 under ticker symbol 'VIRX' Cash and cash equivalents of over $120 million as...
There’s Blood In The Streets, But Opportunity Could Be Presenting Itself With Penny Stocks What’s your strategy for finding the best penny stocks to buy ? At the top of my mind, there are a few things to look at. One of them is industry sentiment. Several industries ha...
Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its Combination Product Candidate for the Treatment of Epstein-Barr Virus-associated Lymphoma Resulting patent to extend Viracta's intellectual property protection into at least 20...